<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02463799</url>
  </required_header>
  <id_info>
    <org_study_id>J1522</org_study_id>
    <secondary_id>IRB00056435</secondary_id>
    <nct_id>NCT02463799</nct_id>
  </id_info>
  <brief_title>Study of Sipuleucel-T W/ or W/O Radium-223 in Men With Asymptomatic or Minimally Symptomatic Bone-MCRPC</brief_title>
  <official_title>A Phase 2 Study of Sipuleucel-T With or Without Radium-223 in Men With Asymptomatic or Minimally Symptomatic Bone-Metastatic Castrate-Resistant Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dendreon</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial studies the effect of radium-223 when added to sipuleucel-T for treating&#xD;
      castrate-resistant prostate cancer that has spread to the bone. Sipuleucel-T is an autologous&#xD;
      cellular immunotherapy designed to stimulate an immune response against prostate cancer. It&#xD;
      has been suggested that the immune response may be strengthened by radiation therapy.&#xD;
      Therefore this study is testing whether radium-223 added to sipuleucel-T increases the immune&#xD;
      response and anti-tumor effect against prostate cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized study designed to assess the antigen-specific immune response of&#xD;
      sipuleucel-T with or without radium-223. Eligible subjects will be registered and randomly&#xD;
      assigned in a 1:1 ratio to receive sipuleucel-T and radium-223 or sipuleucel-T alone.&#xD;
&#xD;
      Subjects in both arms (sipuleucel-T and radium) will undergo a standard 1.5 to 2.0 blood&#xD;
      volume leukapheresis, followed approximately 3 days later by an IV infusion of sipuleucel-T.&#xD;
      This process will occur a total of 3 times at approximately 2-week intervals. Subjects in Arm&#xD;
      1 will receive a total of 6 infusions of radium-223 at IV dose of 50 kBq/kg at 4-week&#xD;
      interval.&#xD;
&#xD;
      All participants are allowed to receive the best supportive care which includes secondary&#xD;
      hormonal manipulation as required. No chemotherapy, external-beam radiation, or other&#xD;
      radionuclides are allowed while on active treatment but are permitted after completion of&#xD;
      active treatment. Glucocorticoid-containing treatments should be minimized to less than the&#xD;
      equivalent dose of prednisone 10mg daily if feasible for the 3 months following sipuleucel-T&#xD;
      therapy. All patients continue medical or surgical castration during treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 22, 2016</start_date>
  <completion_date type="Actual">December 12, 2019</completion_date>
  <primary_completion_date type="Actual">December 12, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Immune Responses to Treatment With Sipuleucel-T (With or Without Radium-223) Measured by Peripheral PA2024 T-cell Proliferation</measure>
    <time_frame>6 weeks</time_frame>
    <description>Peripheral PA2024-specific T-cell proliferation responses using a 3H-thymidine incorporation assay at 6 weeks after the first dose of sipuleucel-T, measured by SI (Stimulation Index [3H-thymidine incorporation in the presence of antigen divided by 3H-thymidine incorporation with media alone] ).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Peripheral PA2024 Specific T-cell Proliferation as Measured by Stimulation Index Over Time</measure>
    <time_frame>Up to 52 weeks</time_frame>
    <description>Mean peripheral PA2024 specific T-cell proliferation using a 3H-thymidine incorporation assay reported as SI (Stimulation Index [3H-thymidine incorporation in the presence of antigen divided by 3H-thymidine incorporation with media alone] ) at baseline and 6, 10, 14, 26, 39, and 52 weeks after the first infusion of sipuleucel-T.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Radiographic or Clinical Progression</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Number of weeks from baseline until radiographic or clinical progression, whichever comes first. Radiographic progression is assessed by RECIST (Response Evaluation Criteria in Solid Tumors) and PCWG2 criteria (Prostate Cancer Working Group 2). Per RECIST, progression is defined as ≥ 20% and ≥ 5 mm from nadir of the sum of the diameters of target lesions. Per PCWG2 criteria, radiographic progression is defined as ≥ 20% sum of the longest diameter of target lesions, or ≥ 2 new lesions on bone scan from baseline. Clinical progression is defined as new spinal cord or nerve root compression, new pathologic fracture or use of opioid analgesics for cancer-related pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PSA50 Response (at Least a 50% Decline in PSA)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Number of participants with PSA50 response defined as at least a 50% decline in Prostate Specific Antigen (PSA) from baseline value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peripheral PAP Specific T-cell Proliferation as Measured by Stimulation Index Over Time</measure>
    <time_frame>Up to 52 weeks</time_frame>
    <description>Mean peripheral PAP specific T-cell proliferation using a 3H-thymidine incorporation assay reported as SI (Stimulation Index [3H-thymidine incorporation in the presence of antigen divided by 3H-thymidine incorporation with media alone] ) at baseline and 6, 10, 14, 26, 39, and 52 weeks after the first infusion of sipuleucel-T</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peripheral PA2024 Specific T-cell Activation</measure>
    <time_frame>Up to 52 weeks</time_frame>
    <description>Mean peripheral PA2024 specific T-cell activation to sipuleucel-T using interferon gamma (IFNγ) enzyme-linked immunosorbent spot (ELISPOT), as measured by cells per 300,000 PBMCs at baseline and weeks 6, 10, 14, 26, 39, and 52 weeks after the first infusion of sipuleucel-T.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peripheral PAP Specific T-cell Activation</measure>
    <time_frame>Up to 52 weeks</time_frame>
    <description>Mean peripheral PAP specific T-cell activation to sipuleucel-T using interferon gamma (IFNγ) enzyme-linked immunosorbent spot (ELISPOT) measured as cells per 300,000 PBMCs at baseline and weeks 6, 10, 14, 26, 39, and 52 weeks after the first infusion of sipuleucel-T.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PA2024 Specific Antibody (IgM) Response</measure>
    <time_frame>Up to 52 weeks</time_frame>
    <description>Mean titer of PA2024 specific antibody (IgM) response to sipuleucel-T using enzyme-linked immunosorbent assay (ELISA) at baseline and weeks 6, 10, 14, 26, 39, and 52 weeks after the first infusion of sipuleucel-T.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PA2024 Specific Antibody (IgG) Response</measure>
    <time_frame>Up to 52 weeks</time_frame>
    <description>Mean titer of PA2024 specific antibody (IgG) response to sipuleucel-T using enzyme-linked immunosorbent assay (ELISA) at baseline and weeks 6, 10, 14, 26, 39, and 52 weeks after the first infusion of sipuleucel-T.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PAP Specific Antibody (IgG) Response Over Time</measure>
    <time_frame>Up to 52 weeks</time_frame>
    <description>Mean titer of PAP specific antibody (IgG) response to sipuleucel-T using enzyme-linked immunosorbent assay (ELISA) at baseline and weeks 6, 10, 14, 26, 39, and 52 weeks after the first infusion of sipuleucel-T.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PAP Specific Antibody (IgM) Response</measure>
    <time_frame>Up to 52 weeks</time_frame>
    <description>Mean titer of PAP specific antibody (IgM) response to sipuleucel-T using enzyme-linked immunosorbent assay (ELISA) at baseline and weeks 6, 10, 14, 26, 39, and 52 weeks after the first infusion of sipuleucel-T.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sipuleucel-T Product Immune Parameters as Assessed by Number of CD54+ Cells</measure>
    <time_frame>Up to 4 weeks</time_frame>
    <description>Mean number of CD54 + cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sipuleucel-T Product Immune Parameters as Assessed by CD54+ Upregulation</measure>
    <time_frame>Up to 4 weeks</time_frame>
    <description>Mean CD54+ Upregulation of Sipuleucel-T</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sipuleucel-T Product Immune Parameters as Assessed by Total Nucleated Cell Count</measure>
    <time_frame>Up to 4 weeks</time_frame>
    <description>Mean number of Total Nucleated Cells</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>sipuleucel-T and radium 223 combination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Radium-223 will be administered by intravenous injection over 1 minute at 50kbq (1.35 microcurie) per kg body weight per standard of care every 4 weeks at weeks 0, 4, 8, 12, 16, and 20&#xD;
Sipuleucel-T will be administered intravenously per standard of care every 2 weeks at weeks 6, 8, and 10</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sipuleucel-T alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sipuleucel-T will be administered intravenously per standard of care every 2 weeks at weeks 6, 8, and 10</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Radium-223</intervention_name>
    <description>6 infusions of radium-223 with 3 infusions of sipuleucel-T starting after second dose of radium-223</description>
    <arm_group_label>sipuleucel-T and radium 223 combination</arm_group_label>
    <other_name>Xofigo, BAY88-8223</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Sipuleucel-T</intervention_name>
    <description>3 infusions of sipuleucel-T alone</description>
    <arm_group_label>sipuleucel-T alone</arm_group_label>
    <arm_group_label>sipuleucel-T and radium 223 combination</arm_group_label>
    <other_name>Provenge</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Written informed consent provided prior to initiation of study procedures&#xD;
&#xD;
          2. Age ≥ 18 years&#xD;
&#xD;
          3. Histologically documented adenocarcinoma prostate cancer confirmed by a pathology&#xD;
             report from prostate biopsy or a radical prostatectomy specimen. If prostatic tumor is&#xD;
             of mixed histology, &gt; 50% of the tumor must be adenocarcinoma&#xD;
&#xD;
          4. Bone metastases as manifested by one or more lesions on a bone scan performed within 2&#xD;
             months of screening&#xD;
&#xD;
          5. Castrate-resistant prostate cancer, in the setting of castrate levels of testosterone&#xD;
             (≤ 50 ng/dL), defined as current or historical evidence of disease progression&#xD;
             concomitant with surgical castration or androgen deprivation therapy (ADT), as&#xD;
             demonstrated by two consecutive rises in PSA OR new lesions on bone scan:&#xD;
&#xD;
               -  PSA progression will be defined as 2 rising PSA values compared to a reference&#xD;
                  value, measured at least 7 days apart and the second value is ≥ 2 ng/mL [1]. It&#xD;
                  must be documented within 2 months of screening.&#xD;
&#xD;
               -  Appearance of one or more new areas of abnormal uptake on bone scan when compared&#xD;
                  to imaging studies acquired during castration therapy or against the&#xD;
                  precastration studies if there was no response. Increased uptake of pre-existing&#xD;
                  lesions on bone scan does not constitute progression. It must be documented&#xD;
                  within 4 months of screening&#xD;
&#xD;
          6. Serum PSA ≥ 2.0 ng/mL&#xD;
&#xD;
          7. Screening ECOG perf status ≤ 1&#xD;
&#xD;
          8. Asymptomatic or minimally symptomatic disease (no narcotic analgesic; other analgesics&#xD;
             use is allowed)&#xD;
&#xD;
          9. Prior abiraterone and enzalutamide are permitted, but not required&#xD;
&#xD;
         10. Concurrent osteoclast-inhibitory therapies (zoledronic acid, denosumab) are permitted&#xD;
             if patients have been on a stable dose for at least 1 month&#xD;
&#xD;
         11. Adequate screening hematologic, renal, and liver function as evidenced by laboratory&#xD;
             test results within the following ranges ≤ 28 days prior to registration:&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) ≥ 1.5 x109/L&#xD;
&#xD;
               -  Platelet count ≥ 100 x109/L&#xD;
&#xD;
               -  Hemoglobin ≥ 10.0 g/dL&#xD;
&#xD;
               -  Total bilirubin level ≤ 1.5 x institutional upper limit of normal (ULN)&#xD;
&#xD;
               -  Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x ULN&#xD;
&#xD;
               -  Creatinine ≤ 1.5 x ULN&#xD;
&#xD;
               -  Albumin &gt; 25 g/L&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. The presence of known lung or liver metastases greater than 1.0 cm in the long axis&#xD;
             diameter&#xD;
&#xD;
          2. The presence of lymphadenopathy greater than 3 cm in the short-axis diameter&#xD;
&#xD;
          3. The presence of known brain metastases&#xD;
&#xD;
          4. Spinal cord compression, imminent long bone fracture, or any other condition that, in&#xD;
             the opinion of the investigator, is likely to require radiation therapy and/or&#xD;
             steroids for pain control during the active phase&#xD;
&#xD;
          5. Previous treatment with chemotherapy for mCRPC (adjuvant chemotherapy is permitted),&#xD;
             or chemotherapy for any reason within 2 years prior to registration&#xD;
&#xD;
          6. Intention to receive chemotherapy within 6 months after enrollment in protocol therapy&#xD;
&#xD;
          7. History of radiation therapy, either via external beam or brachytherapy within 28 days&#xD;
             prior to registration&#xD;
&#xD;
          8. Systemic radiotherapy with strontium-89, samarium-153, rhenium-186 or rhenium-188 for&#xD;
             the treatment of bony metastases within previous 24 weeks&#xD;
&#xD;
          9. Prior history of other cancers (except non-melanoma skin cancers or low-grade&#xD;
             low-stage urothelial cancers)&#xD;
&#xD;
         10. Use of prednisone or equivalent systemic corticosteroid within 2 weeks of treatment.&#xD;
             Use of inhaled, intranasal, intra-articular, and topical steroids is allowed. Oral or&#xD;
             IV steroids to prevent or treat IV contrast reactions are allowed&#xD;
&#xD;
         11. Use of opioid analgesics for cancer-related pain&#xD;
&#xD;
         12. Use of experimental drug within 4 weeks of treatment&#xD;
&#xD;
         13. Uncontrolled medical conditions including diabetes, heart failure, COPD, ulcerative&#xD;
             colitis, or Crohn's disease&#xD;
&#xD;
         14. Uncontrolled fecal incontinence&#xD;
&#xD;
         15. Any medical intervention, any other condition, or any other circumstance which, in the&#xD;
             opinion of the investigator, could compromise adherence with study requirements or&#xD;
             otherwise compromise the study's objectives&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emmanuel Antonarakis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sibley Memorial Hospital</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tulane Cancer Center</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Marshall CH, Fu W, Wang H, Park JC, DeWeese TL, Tran PT, Song DY, King S, Afful M, Hurrelbrink J, Manogue C, Cotogno P, Moldawer NP, Barata PC, Drake CG, Posadas EM, Armstrong AJ, Sartor O, Antonarakis ES. Randomized Phase II Trial of Sipuleucel-T with or without Radium-223 in Men with Bone-metastatic Castration-resistant Prostate Cancer. Clin Cancer Res. 2021 Mar 15;27(6):1623-1630. doi: 10.1158/1078-0432.CCR-20-4476. Epub 2021 Jan 15.</citation>
    <PMID>33451978</PMID>
  </results_reference>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>May 21, 2015</study_first_submitted>
  <study_first_submitted_qc>June 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 4, 2015</study_first_posted>
  <results_first_submitted>June 15, 2021</results_first_submitted>
  <results_first_submitted_qc>June 15, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">July 8, 2021</results_first_posted>
  <last_update_submitted>June 15, 2021</last_update_submitted>
  <last_update_submitted_qc>June 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>prostatic neoplasms</keyword>
  <keyword>castration-resistant</keyword>
  <keyword>bone metastasis</keyword>
  <keyword>radium-223</keyword>
  <keyword>sipuleucel-T</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 21, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/99/NCT02463799/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>One screen failure and one withdrew consent prior to randomization, two participants withdrew prior to receiving treatment</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Sipuleucel-T and Radium 223 Combination</title>
          <description>Radium-223 will be administered by intravenous injection over 1 minute at 50kbq (1.35 microcurie) per kg body weight per standard of care every 4 weeks at weeks 0, 4, 8, 12, 16, and 20&#xD;
Sipuleucel-T will be administered intravenously per standard of care every 2 weeks at weeks 6, 8, and 10&#xD;
Radium-223: 6 infusions of radium-223 with 3 infusions of sipuleucel-T starting after second dose of radium-223&#xD;
Sipuleucel-T: 3 infusions of sipuleucel-T alone</description>
        </group>
        <group group_id="P2">
          <title>Sipuleucel-T Alone</title>
          <description>Sipuleucel-T will be administered intravenously per standard of care every 2 weeks at weeks 6, 8, and 10&#xD;
Sipuleucel-T: 3 infusions of sipuleucel-T alone</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sipuleucel-T and Radium 223 Combination</title>
          <description>Radium-223 will be administered by intravenous injection over 1 minute at 50kbq (1.35 microcurie) per kg body weight per standard of care every 4 weeks at weeks 0, 4, 8, 12, 16, and 20&#xD;
Sipuleucel-T will be administered intravenously per standard of care every 2 weeks at weeks 6, 8, and 10&#xD;
Radium-223: 6 infusions of radium-223 with 3 infusions of sipuleucel-T starting after second dose of radium-223&#xD;
Sipuleucel-T: 3 infusions of sipuleucel-T alone</description>
        </group>
        <group group_id="B2">
          <title>Sipuleucel-T Alone</title>
          <description>Sipuleucel-T will be administered intravenously per standard of care every 2 weeks at weeks 6, 8, and 10&#xD;
Sipuleucel-T: 3 infusions of sipuleucel-T alone</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
            <count group_id="B2" value="16"/>
            <count group_id="B3" value="32"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71.6" lower_limit="64" upper_limit="88"/>
                    <measurement group_id="B2" value="70.3" lower_limit="57" upper_limit="86"/>
                    <measurement group_id="B3" value="71" lower_limit="57" upper_limit="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Immune Responses to Treatment With Sipuleucel-T (With or Without Radium-223) Measured by Peripheral PA2024 T-cell Proliferation</title>
        <description>Peripheral PA2024-specific T-cell proliferation responses using a 3H-thymidine incorporation assay at 6 weeks after the first dose of sipuleucel-T, measured by SI (Stimulation Index [3H-thymidine incorporation in the presence of antigen divided by 3H-thymidine incorporation with media alone] ).</description>
        <time_frame>6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sipuleucel-T and Radium 223 Combination</title>
            <description>Radium-223 will be administered by intravenous injection over 1 minute at 50kbq (1.35 microcurie) per kg body weight per standard of care every 4 weeks at weeks 0, 4, 8, 12, 16, and 20&#xD;
Sipuleucel-T will be administered intravenously per standard of care every 2 weeks at weeks 6, 8, and 10&#xD;
Radium-223: 6 infusions of radium-223 with 3 infusions of sipuleucel-T starting after second dose of radium-223&#xD;
Sipuleucel-T: 3 infusions of sipuleucel-T alone</description>
          </group>
          <group group_id="O2">
            <title>Sipuleucel-T Alone</title>
            <description>Sipuleucel-T will be administered intravenously per standard of care every 2 weeks at weeks 6, 8, and 10&#xD;
Sipuleucel-T: 3 infusions of sipuleucel-T alone</description>
          </group>
        </group_list>
        <measure>
          <title>Immune Responses to Treatment With Sipuleucel-T (With or Without Radium-223) Measured by Peripheral PA2024 T-cell Proliferation</title>
          <description>Peripheral PA2024-specific T-cell proliferation responses using a 3H-thymidine incorporation assay at 6 weeks after the first dose of sipuleucel-T, measured by SI (Stimulation Index [3H-thymidine incorporation in the presence of antigen divided by 3H-thymidine incorporation with media alone] ).</description>
          <units>fold change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.0" lower_limit="4.12" upper_limit="20.2"/>
                    <measurement group_id="O2" value="22.4" lower_limit="17.2" upper_limit="31.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peripheral PA2024 Specific T-cell Proliferation as Measured by Stimulation Index Over Time</title>
        <description>Mean peripheral PA2024 specific T-cell proliferation using a 3H-thymidine incorporation assay reported as SI (Stimulation Index [3H-thymidine incorporation in the presence of antigen divided by 3H-thymidine incorporation with media alone] ) at baseline and 6, 10, 14, 26, 39, and 52 weeks after the first infusion of sipuleucel-T.</description>
        <time_frame>Up to 52 weeks</time_frame>
        <population>Data was only collected from 13 out of 16 participants in the Sipuleucel-T and radium 223 combination arm and 10 out of 16 participants in the Sipuleucel-T arm</population>
        <group_list>
          <group group_id="O1">
            <title>Sipuleucel-T and Radium 223 Combination</title>
            <description>Radium-223 will be administered by intravenous injection over 1 minute at 50kbq (1.35 microcurie) per kg body weight per standard of care every 4 weeks at weeks 0, 4, 8, 12, 16, and 20&#xD;
Sipuleucel-T will be administered intravenously per standard of care every 2 weeks at weeks 6, 8, and 10&#xD;
Radium-223: 6 infusions of radium-223 with 3 infusions of sipuleucel-T starting after second dose of radium-223&#xD;
Sipuleucel-T: 3 infusions of sipuleucel-T alone</description>
          </group>
          <group group_id="O2">
            <title>Sipuleucel-T Alone</title>
            <description>Sipuleucel-T will be administered intravenously per standard of care every 2 weeks at weeks 6, 8, and 10&#xD;
Sipuleucel-T: 3 infusions of sipuleucel-T alone</description>
          </group>
        </group_list>
        <measure>
          <title>Peripheral PA2024 Specific T-cell Proliferation as Measured by Stimulation Index Over Time</title>
          <description>Mean peripheral PA2024 specific T-cell proliferation using a 3H-thymidine incorporation assay reported as SI (Stimulation Index [3H-thymidine incorporation in the presence of antigen divided by 3H-thymidine incorporation with media alone] ) at baseline and 6, 10, 14, 26, 39, and 52 weeks after the first infusion of sipuleucel-T.</description>
          <population>Data was only collected from 13 out of 16 participants in the Sipuleucel-T and radium 223 combination arm and 10 out of 16 participants in the Sipuleucel-T arm</population>
          <units>Stimulation Index</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" lower_limit="1.0" upper_limit="2.2"/>
                    <measurement group_id="O2" value="1.4" lower_limit="1.2" upper_limit="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.7" lower_limit="4.4" upper_limit="37.0"/>
                    <measurement group_id="O2" value="49.8" lower_limit="30.5" upper_limit="44.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.8" lower_limit="8.6" upper_limit="34.2"/>
                    <measurement group_id="O2" value="42.0" lower_limit="26.3" upper_limit="56.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.0" lower_limit="7.0" upper_limit="21.8"/>
                    <measurement group_id="O2" value="42.2" lower_limit="32.1" upper_limit="56.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.2" lower_limit="12.2" upper_limit="26.4"/>
                    <measurement group_id="O2" value="25.6" lower_limit="15.4" upper_limit="36.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 39</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.7" lower_limit="5.4" upper_limit="22.3"/>
                    <measurement group_id="O2" value="25.3" lower_limit="25.3" upper_limit="25.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.5" lower_limit="4.4" upper_limit="23.3"/>
                    <measurement group_id="O2" value="11.8" lower_limit="11.8" upper_limit="11.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Radiographic or Clinical Progression</title>
        <description>Number of weeks from baseline until radiographic or clinical progression, whichever comes first. Radiographic progression is assessed by RECIST (Response Evaluation Criteria in Solid Tumors) and PCWG2 criteria (Prostate Cancer Working Group 2). Per RECIST, progression is defined as ≥ 20% and ≥ 5 mm from nadir of the sum of the diameters of target lesions. Per PCWG2 criteria, radiographic progression is defined as ≥ 20% sum of the longest diameter of target lesions, or ≥ 2 new lesions on bone scan from baseline. Clinical progression is defined as new spinal cord or nerve root compression, new pathologic fracture or use of opioid analgesics for cancer-related pain.</description>
        <time_frame>Up to 2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sipuleucel-T and Radium 223 Combination</title>
            <description>Radium-223 will be administered by intravenous injection over 1 minute at 50kbq (1.35 microcurie) per kg body weight per standard of care every 4 weeks at weeks 0, 4, 8, 12, 16, and 20&#xD;
Sipuleucel-T will be administered intravenously per standard of care every 2 weeks at weeks 6, 8, and 10&#xD;
Radium-223: 6 infusions of radium-223 with 3 infusions of sipuleucel-T starting after second dose of radium-223&#xD;
Sipuleucel-T: 3 infusions of sipuleucel-T alone</description>
          </group>
          <group group_id="O2">
            <title>Sipuleucel-T Alone</title>
            <description>Sipuleucel-T will be administered intravenously per standard of care every 2 weeks at weeks 6, 8, and 10&#xD;
Sipuleucel-T: 3 infusions of sipuleucel-T alone</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Radiographic or Clinical Progression</title>
          <description>Number of weeks from baseline until radiographic or clinical progression, whichever comes first. Radiographic progression is assessed by RECIST (Response Evaluation Criteria in Solid Tumors) and PCWG2 criteria (Prostate Cancer Working Group 2). Per RECIST, progression is defined as ≥ 20% and ≥ 5 mm from nadir of the sum of the diameters of target lesions. Per PCWG2 criteria, radiographic progression is defined as ≥ 20% sum of the longest diameter of target lesions, or ≥ 2 new lesions on bone scan from baseline. Clinical progression is defined as new spinal cord or nerve root compression, new pathologic fracture or use of opioid analgesics for cancer-related pain.</description>
          <units>WEEKS</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.7" lower_limit="18.9" upper_limit="NA">Upper bound of median not reached, therefore cannot be calculated</measurement>
                    <measurement group_id="O2" value="11.9" lower_limit="8.0" upper_limit="15.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PSA50 Response (at Least a 50% Decline in PSA)</title>
        <description>Number of participants with PSA50 response defined as at least a 50% decline in Prostate Specific Antigen (PSA) from baseline value</description>
        <time_frame>Up to 2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sipuleucel-T and Radium 223 Combination</title>
            <description>Radium-223 will be administered by intravenous injection over 1 minute at 50kbq (1.35 microcurie) per kg body weight per standard of care every 4 weeks at weeks 0, 4, 8, 12, 16, and 20&#xD;
Sipuleucel-T will be administered intravenously per standard of care every 2 weeks at weeks 6, 8, and 10&#xD;
Radium-223: 6 infusions of radium-223 with 3 infusions of sipuleucel-T starting after second dose of radium-223&#xD;
Sipuleucel-T: 3 infusions of sipuleucel-T alone</description>
          </group>
          <group group_id="O2">
            <title>Sipuleucel-T Alone</title>
            <description>Sipuleucel-T will be administered intravenously per standard of care every 2 weeks at weeks 6, 8, and 10&#xD;
Sipuleucel-T: 3 infusions of sipuleucel-T alone</description>
          </group>
        </group_list>
        <measure>
          <title>PSA50 Response (at Least a 50% Decline in PSA)</title>
          <description>Number of participants with PSA50 response defined as at least a 50% decline in Prostate Specific Antigen (PSA) from baseline value</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peripheral PAP Specific T-cell Proliferation as Measured by Stimulation Index Over Time</title>
        <description>Mean peripheral PAP specific T-cell proliferation using a 3H-thymidine incorporation assay reported as SI (Stimulation Index [3H-thymidine incorporation in the presence of antigen divided by 3H-thymidine incorporation with media alone] ) at baseline and 6, 10, 14, 26, 39, and 52 weeks after the first infusion of sipuleucel-T</description>
        <time_frame>Up to 52 weeks</time_frame>
        <population>Data was only collected from 13 out of 16 participants in the Sipuleucel-T and radium 223 combination arm and 10 out of 16 participants in the Sipuleucel-T arm</population>
        <group_list>
          <group group_id="O1">
            <title>Sipuleucel-T and Radium 223 Combination</title>
            <description>Radium-223 will be administered by intravenous injection over 1 minute at 50kbq (1.35 microcurie) per kg body weight per standard of care every 4 weeks at weeks 0, 4, 8, 12, 16, and 20&#xD;
Sipuleucel-T will be administered intravenously per standard of care every 2 weeks at weeks 6, 8, and 10&#xD;
Radium-223: 6 infusions of radium-223 with 3 infusions of sipuleucel-T starting after second dose of radium-223&#xD;
Sipuleucel-T: 3 infusions of sipuleucel-T alone</description>
          </group>
          <group group_id="O2">
            <title>Sipuleucel-T Alone</title>
            <description>Sipuleucel-T will be administered intravenously per standard of care every 2 weeks at weeks 6, 8, and 10&#xD;
Sipuleucel-T: 3 infusions of sipuleucel-T alone</description>
          </group>
        </group_list>
        <measure>
          <title>Peripheral PAP Specific T-cell Proliferation as Measured by Stimulation Index Over Time</title>
          <description>Mean peripheral PAP specific T-cell proliferation using a 3H-thymidine incorporation assay reported as SI (Stimulation Index [3H-thymidine incorporation in the presence of antigen divided by 3H-thymidine incorporation with media alone] ) at baseline and 6, 10, 14, 26, 39, and 52 weeks after the first infusion of sipuleucel-T</description>
          <population>Data was only collected from 13 out of 16 participants in the Sipuleucel-T and radium 223 combination arm and 10 out of 16 participants in the Sipuleucel-T arm</population>
          <units>Stimulation Index</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" lower_limit="0.7" upper_limit="1.0"/>
                    <measurement group_id="O2" value="1.2" lower_limit="1.0" upper_limit="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" lower_limit="0.9" upper_limit="1.4"/>
                    <measurement group_id="O2" value="12.5" lower_limit="1.3" upper_limit="4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1" lower_limit="0.8" upper_limit="3.8"/>
                    <measurement group_id="O2" value="5.7" lower_limit="1.2" upper_limit="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" lower_limit="0.7" upper_limit="2.3"/>
                    <measurement group_id="O2" value="6.1" lower_limit="1.0" upper_limit="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9" lower_limit="0.7" upper_limit="3.8"/>
                    <measurement group_id="O2" value="1.5" lower_limit="1.0" upper_limit="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 39</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1" lower_limit="1.3" upper_limit="3.5"/>
                    <measurement group_id="O2" value="1.8" lower_limit="1.8" upper_limit="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" lower_limit="0.5" upper_limit="3.1"/>
                    <measurement group_id="O2" value="1.9" lower_limit="1.9" upper_limit="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peripheral PA2024 Specific T-cell Activation</title>
        <description>Mean peripheral PA2024 specific T-cell activation to sipuleucel-T using interferon gamma (IFNγ) enzyme-linked immunosorbent spot (ELISPOT), as measured by cells per 300,000 PBMCs at baseline and weeks 6, 10, 14, 26, 39, and 52 weeks after the first infusion of sipuleucel-T.</description>
        <time_frame>Up to 52 weeks</time_frame>
        <population>Data was only collected from 13 out of 16 participants in the Sipuleucel-T and radium 223 combination arm and 10 out of 16 participants in the Sipuleucel-T arm</population>
        <group_list>
          <group group_id="O1">
            <title>Sipuleucel-T and Radium 223 Combination</title>
            <description>Radium-223 will be administered by intravenous injection over 1 minute at 50kbq (1.35 microcurie) per kg body weight per standard of care every 4 weeks at weeks 0, 4, 8, 12, 16, and 20&#xD;
Sipuleucel-T will be administered intravenously per standard of care every 2 weeks at weeks 6, 8, and 10&#xD;
Radium-223: 6 infusions of radium-223 with 3 infusions of sipuleucel-T starting after second dose of radium-223&#xD;
Sipuleucel-T: 3 infusions of sipuleucel-T alone</description>
          </group>
          <group group_id="O2">
            <title>Sipuleucel-T Alone</title>
            <description>Sipuleucel-T will be administered intravenously per standard of care every 2 weeks at weeks 6, 8, and 10&#xD;
Sipuleucel-T: 3 infusions of sipuleucel-T alone</description>
          </group>
        </group_list>
        <measure>
          <title>Peripheral PA2024 Specific T-cell Activation</title>
          <description>Mean peripheral PA2024 specific T-cell activation to sipuleucel-T using interferon gamma (IFNγ) enzyme-linked immunosorbent spot (ELISPOT), as measured by cells per 300,000 PBMCs at baseline and weeks 6, 10, 14, 26, 39, and 52 weeks after the first infusion of sipuleucel-T.</description>
          <population>Data was only collected from 13 out of 16 participants in the Sipuleucel-T and radium 223 combination arm and 10 out of 16 participants in the Sipuleucel-T arm</population>
          <units>cells per 300,000 PBMCs</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6" lower_limit="1.0" upper_limit="1.8"/>
                    <measurement group_id="O2" value="6.0" lower_limit="1.0" upper_limit="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.5" lower_limit="17.5" upper_limit="127.7"/>
                    <measurement group_id="O2" value="194.3" lower_limit="34.2" upper_limit="349.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.9" lower_limit="8.0" upper_limit="133.7"/>
                    <measurement group_id="O2" value="116.4" lower_limit="14.3" upper_limit="232.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.6" lower_limit="17.3" upper_limit="115.3"/>
                    <measurement group_id="O2" value="137.8" lower_limit="41.7" upper_limit="164.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.7" lower_limit="12.7" upper_limit="137.0"/>
                    <measurement group_id="O2" value="169.9" lower_limit="112.7" upper_limit="247.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 39</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.3" lower_limit="6.4" upper_limit="43.8"/>
                    <measurement group_id="O2" value="19.0" lower_limit="19.0" upper_limit="19.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.4" lower_limit="12.0" upper_limit="33.2"/>
                    <measurement group_id="O2" value="26.0" lower_limit="26.0" upper_limit="26.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peripheral PAP Specific T-cell Activation</title>
        <description>Mean peripheral PAP specific T-cell activation to sipuleucel-T using interferon gamma (IFNγ) enzyme-linked immunosorbent spot (ELISPOT) measured as cells per 300,000 PBMCs at baseline and weeks 6, 10, 14, 26, 39, and 52 weeks after the first infusion of sipuleucel-T.</description>
        <time_frame>Up to 52 weeks</time_frame>
        <population>Data was only collected from 13 out of 16 participants in the Sipuleucel-T and radium 223 combination arm and 10 out of 16 participants in the Sipuleucel-T arm</population>
        <group_list>
          <group group_id="O1">
            <title>Sipuleucel-T and Radium 223 Combination</title>
            <description>Radium-223 will be administered by intravenous injection over 1 minute at 50kbq (1.35 microcurie) per kg body weight per standard of care every 4 weeks at weeks 0, 4, 8, 12, 16, and 20&#xD;
Sipuleucel-T will be administered intravenously per standard of care every 2 weeks at weeks 6, 8, and 10&#xD;
Radium-223: 6 infusions of radium-223 with 3 infusions of sipuleucel-T starting after second dose of radium-223&#xD;
Sipuleucel-T: 3 infusions of sipuleucel-T alone</description>
          </group>
          <group group_id="O2">
            <title>Sipuleucel-T Alone</title>
            <description>Sipuleucel-T will be administered intravenously per standard of care every 2 weeks at weeks 6, 8, and 10&#xD;
Sipuleucel-T: 3 infusions of sipuleucel-T alone</description>
          </group>
        </group_list>
        <measure>
          <title>Peripheral PAP Specific T-cell Activation</title>
          <description>Mean peripheral PAP specific T-cell activation to sipuleucel-T using interferon gamma (IFNγ) enzyme-linked immunosorbent spot (ELISPOT) measured as cells per 300,000 PBMCs at baseline and weeks 6, 10, 14, 26, 39, and 52 weeks after the first infusion of sipuleucel-T.</description>
          <population>Data was only collected from 13 out of 16 participants in the Sipuleucel-T and radium 223 combination arm and 10 out of 16 participants in the Sipuleucel-T arm</population>
          <units>cells per 300,000 PBMCs</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" lower_limit="0.0" upper_limit="1.8"/>
                    <measurement group_id="O2" value="4.8" lower_limit="0.0" upper_limit="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.8" lower_limit="0.0" upper_limit="2.8"/>
                    <measurement group_id="O2" value="10.9" lower_limit="0.0" upper_limit="18.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.1" lower_limit="0.0" upper_limit="3.7"/>
                    <measurement group_id="O2" value="19.4" lower_limit="0.0" upper_limit="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.2" lower_limit="0.2" upper_limit="5.3"/>
                    <measurement group_id="O2" value="9.0" lower_limit="0.0" upper_limit="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.4" lower_limit="0.7" upper_limit="2.3"/>
                    <measurement group_id="O2" value="1.0" lower_limit="0.0" upper_limit="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 39</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" lower_limit="0.3" upper_limit="2.8"/>
                    <measurement group_id="O2" value="1.3" lower_limit="1.3" upper_limit="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" lower_limit="0.8" upper_limit="4.5"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PA2024 Specific Antibody (IgM) Response</title>
        <description>Mean titer of PA2024 specific antibody (IgM) response to sipuleucel-T using enzyme-linked immunosorbent assay (ELISA) at baseline and weeks 6, 10, 14, 26, 39, and 52 weeks after the first infusion of sipuleucel-T.</description>
        <time_frame>Up to 52 weeks</time_frame>
        <population>Data was only collected from 14 out of 16 participants in the Sipuleucel-T and radium 223 combination arm and 14 out of 16 participants in the Sipuleucel-T arm</population>
        <group_list>
          <group group_id="O1">
            <title>Sipuleucel-T and Radium 223 Combination</title>
            <description>Radium-223 will be administered by intravenous injection over 1 minute at 50kbq (1.35 microcurie) per kg body weight per standard of care every 4 weeks at weeks 0, 4, 8, 12, 16, and 20&#xD;
Sipuleucel-T will be administered intravenously per standard of care every 2 weeks at weeks 6, 8, and 10&#xD;
Radium-223: 6 infusions of radium-223 with 3 infusions of sipuleucel-T starting after second dose of radium-223&#xD;
Sipuleucel-T: 3 infusions of sipuleucel-T alone</description>
          </group>
          <group group_id="O2">
            <title>Sipuleucel-T Alone</title>
            <description>Sipuleucel-T will be administered intravenously per standard of care every 2 weeks at weeks 6, 8, and 10&#xD;
Sipuleucel-T: 3 infusions of sipuleucel-T alone</description>
          </group>
        </group_list>
        <measure>
          <title>PA2024 Specific Antibody (IgM) Response</title>
          <description>Mean titer of PA2024 specific antibody (IgM) response to sipuleucel-T using enzyme-linked immunosorbent assay (ELISA) at baseline and weeks 6, 10, 14, 26, 39, and 52 weeks after the first infusion of sipuleucel-T.</description>
          <population>Data was only collected from 14 out of 16 participants in the Sipuleucel-T and radium 223 combination arm and 14 out of 16 participants in the Sipuleucel-T arm</population>
          <units>titer</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1567.9" lower_limit="200" upper_limit="1600"/>
                    <measurement group_id="O2" value="2253.6" lower_limit="350" upper_limit="3200"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="108941.7" lower_limit="19400" upper_limit="204800"/>
                    <measurement group_id="O2" value="164114.3" lower_limit="102400" upper_limit="204800"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="165434.6" lower_limit="25600" upper_limit="204800"/>
                    <measurement group_id="O2" value="214690.9" lower_limit="128000" upper_limit="307200"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101422.7" lower_limit="7200" upper_limit="153600"/>
                    <measurement group_id="O2" value="185600.0" lower_limit="102400" upper_limit="204800"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56586.4" lower_limit="16000" upper_limit="76800"/>
                    <measurement group_id="O2" value="28800.0" lower_limit="17600" upper_limit="40000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 39</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37338.9" lower_limit="3200" upper_limit="51200"/>
                    <measurement group_id="O2" value="204800.0" lower_limit="204800" upper_limit="204800"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28400.0" lower_limit="2800" upper_limit="30400"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PA2024 Specific Antibody (IgG) Response</title>
        <description>Mean titer of PA2024 specific antibody (IgG) response to sipuleucel-T using enzyme-linked immunosorbent assay (ELISA) at baseline and weeks 6, 10, 14, 26, 39, and 52 weeks after the first infusion of sipuleucel-T.</description>
        <time_frame>Up to 52 weeks</time_frame>
        <population>Data was only collected from 14 out of 16 participants in the Sipuleucel-T and radium 223 combination arm and 14 out of 16 participants in the Sipuleucel-T arm</population>
        <group_list>
          <group group_id="O1">
            <title>Sipuleucel-T and Radium 223 Combination</title>
            <description>Radium-223 will be administered by intravenous injection over 1 minute at 50kbq (1.35 microcurie) per kg body weight per standard of care every 4 weeks at weeks 0, 4, 8, 12, 16, and 20&#xD;
Sipuleucel-T will be administered intravenously per standard of care every 2 weeks at weeks 6, 8, and 10&#xD;
Radium-223: 6 infusions of radium-223 with 3 infusions of sipuleucel-T starting after second dose of radium-223&#xD;
Sipuleucel-T: 3 infusions of sipuleucel-T alone</description>
          </group>
          <group group_id="O2">
            <title>Sipuleucel-T Alone</title>
            <description>Sipuleucel-T will be administered intravenously per standard of care every 2 weeks at weeks 6, 8, and 10&#xD;
Sipuleucel-T: 3 infusions of sipuleucel-T alone</description>
          </group>
        </group_list>
        <measure>
          <title>PA2024 Specific Antibody (IgG) Response</title>
          <description>Mean titer of PA2024 specific antibody (IgG) response to sipuleucel-T using enzyme-linked immunosorbent assay (ELISA) at baseline and weeks 6, 10, 14, 26, 39, and 52 weeks after the first infusion of sipuleucel-T.</description>
          <population>Data was only collected from 14 out of 16 participants in the Sipuleucel-T and radium 223 combination arm and 14 out of 16 participants in the Sipuleucel-T arm</population>
          <units>titer</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="382.1" lower_limit="50.0" upper_limit="350"/>
                    <measurement group_id="O2" value="771.4" lower_limit="62.5" upper_limit="800"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1476.9" lower_limit="200.0" upper_limit="1600"/>
                    <measurement group_id="O2" value="7878.6" lower_limit="1000.0" upper_limit="5600"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3442.9" lower_limit="400.0" upper_limit="6400"/>
                    <measurement group_id="O2" value="23272.7" lower_limit="1600.0" upper_limit="6400"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4191.7" lower_limit="350.0" upper_limit="4000"/>
                    <measurement group_id="O2" value="15733.3" lower_limit="800.0" upper_limit="3200"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3568.2" lower_limit="1000.0" upper_limit="6400"/>
                    <measurement group_id="O2" value="7200.0" lower_limit="4400.0" upper_limit="10000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 39</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2738.9" lower_limit="400.0" upper_limit="1600"/>
                    <measurement group_id="O2" value="25600.0" lower_limit="25600.0" upper_limit="25600"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3812.5" lower_limit="612.5" upper_limit="4400"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PAP Specific Antibody (IgG) Response Over Time</title>
        <description>Mean titer of PAP specific antibody (IgG) response to sipuleucel-T using enzyme-linked immunosorbent assay (ELISA) at baseline and weeks 6, 10, 14, 26, 39, and 52 weeks after the first infusion of sipuleucel-T.</description>
        <time_frame>Up to 52 weeks</time_frame>
        <population>Data was only collected from 14 out of 16 participants in the Sipuleucel-T and radium 223 combination arm and 14 out of 16 participants in the Sipuleucel-T arm</population>
        <group_list>
          <group group_id="O1">
            <title>Sipuleucel-T and Radium 223 Combination</title>
            <description>Radium-223 will be administered by intravenous injection over 1 minute at 50kbq (1.35 microcurie) per kg body weight per standard of care every 4 weeks at weeks 0, 4, 8, 12, 16, and 20&#xD;
Sipuleucel-T will be administered intravenously per standard of care every 2 weeks at weeks 6, 8, and 10&#xD;
Radium-223: 6 infusions of radium-223 with 3 infusions of sipuleucel-T starting after second dose of radium-223&#xD;
Sipuleucel-T: 3 infusions of sipuleucel-T alone</description>
          </group>
          <group group_id="O2">
            <title>Sipuleucel-T Alone</title>
            <description>Sipuleucel-T will be administered intravenously per standard of care every 2 weeks at weeks 6, 8, and 10&#xD;
Sipuleucel-T: 3 infusions of sipuleucel-T alone</description>
          </group>
        </group_list>
        <measure>
          <title>PAP Specific Antibody (IgG) Response Over Time</title>
          <description>Mean titer of PAP specific antibody (IgG) response to sipuleucel-T using enzyme-linked immunosorbent assay (ELISA) at baseline and weeks 6, 10, 14, 26, 39, and 52 weeks after the first infusion of sipuleucel-T.</description>
          <population>Data was only collected from 14 out of 16 participants in the Sipuleucel-T and radium 223 combination arm and 14 out of 16 participants in the Sipuleucel-T arm</population>
          <units>titer</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="796.4" lower_limit="50" upper_limit="800"/>
                    <measurement group_id="O2" value="1475.0" lower_limit="125" upper_limit="800"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3765.4" lower_limit="400" upper_limit="1600"/>
                    <measurement group_id="O2" value="10546.4" lower_limit="800" upper_limit="5600"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15125.0" lower_limit="800" upper_limit="11200"/>
                    <measurement group_id="O2" value="44563.6" lower_limit="4800" upper_limit="25600"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6554.2" lower_limit="625" upper_limit="6400"/>
                    <measurement group_id="O2" value="6450.0" lower_limit="2450" upper_limit="12800"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5354.5" lower_limit="400" upper_limit="4800"/>
                    <measurement group_id="O2" value="51400.0" lower_limit="25900" upper_limit="76900"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 39</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3916.7" lower_limit="400" upper_limit="6400"/>
                    <measurement group_id="O2" value="204800.0" lower_limit="204800" upper_limit="204800"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5100" lower_limit="700" upper_limit="8000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PAP Specific Antibody (IgM) Response</title>
        <description>Mean titer of PAP specific antibody (IgM) response to sipuleucel-T using enzyme-linked immunosorbent assay (ELISA) at baseline and weeks 6, 10, 14, 26, 39, and 52 weeks after the first infusion of sipuleucel-T.</description>
        <time_frame>Up to 52 weeks</time_frame>
        <population>Data was only collected from 14 out of 16 participants in the Sipuleucel-T and radium 223 combination arm and 14 out of 16 participants in the Sipuleucel-T arm</population>
        <group_list>
          <group group_id="O1">
            <title>Sipuleucel-T and Radium 223 Combination</title>
            <description>Radium-223 will be administered by intravenous injection over 1 minute at 50kbq (1.35 microcurie) per kg body weight per standard of care every 4 weeks at weeks 0, 4, 8, 12, 16, and 20&#xD;
Sipuleucel-T will be administered intravenously per standard of care every 2 weeks at weeks 6, 8, and 10&#xD;
Radium-223: 6 infusions of radium-223 with 3 infusions of sipuleucel-T starting after second dose of radium-223&#xD;
Sipuleucel-T: 3 infusions of sipuleucel-T alone</description>
          </group>
          <group group_id="O2">
            <title>Sipuleucel-T Alone</title>
            <description>Sipuleucel-T will be administered intravenously per standard of care every 2 weeks at weeks 6, 8, and 10&#xD;
Sipuleucel-T: 3 infusions of sipuleucel-T alone</description>
          </group>
        </group_list>
        <measure>
          <title>PAP Specific Antibody (IgM) Response</title>
          <description>Mean titer of PAP specific antibody (IgM) response to sipuleucel-T using enzyme-linked immunosorbent assay (ELISA) at baseline and weeks 6, 10, 14, 26, 39, and 52 weeks after the first infusion of sipuleucel-T.</description>
          <population>Data was only collected from 14 out of 16 participants in the Sipuleucel-T and radium 223 combination arm and 14 out of 16 participants in the Sipuleucel-T arm</population>
          <units>titer</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4714.3" lower_limit="250" upper_limit="1600"/>
                    <measurement group_id="O2" value="6253.8" lower_limit="400" upper_limit="3200"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99209.1" lower_limit="19200" upper_limit="51200"/>
                    <measurement group_id="O2" value="112114.3" lower_limit="16000" upper_limit="204800"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="183184.6" lower_limit="25600" upper_limit="409600"/>
                    <measurement group_id="O2" value="210909.1" lower_limit="76800" upper_limit="409600"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73250.0" lower_limit="5200" upper_limit="64000"/>
                    <measurement group_id="O2" value="238400.0" lower_limit="166400" upper_limit="409600"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72363.6" lower_limit="12800" upper_limit="38400"/>
                    <measurement group_id="O2" value="205600.0" lower_limit="103600" upper_limit="307600"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 39</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36425.0" lower_limit="5600" upper_limit="25600"/>
                    <measurement group_id="O2" value="409600.0" lower_limit="409600" upper_limit="409600"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33200.0" lower_limit="2800" upper_limit="44800"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sipuleucel-T Product Immune Parameters as Assessed by Number of CD54+ Cells</title>
        <description>Mean number of CD54 + cells</description>
        <time_frame>Up to 4 weeks</time_frame>
        <population>Data was only collected from 14 out of 16 participants in the Sipuleucel-T and radium 223 combination arm and 14 out of 16 participants in the Sipuleucel-T arm</population>
        <group_list>
          <group group_id="O1">
            <title>Sipuleucel-T and Radium 223 Combination</title>
            <description>Radium-223 will be administered by intravenous injection over 1 minute at 50kbq (1.35 microcurie) per kg body weight per standard of care every 4 weeks at weeks 0, 4, 8, 12, 16, and 20&#xD;
Sipuleucel-T will be administered intravenously per standard of care every 2 weeks at weeks 6, 8, and 10&#xD;
Radium-223: 6 infusions of radium-223 with 3 infusions of sipuleucel-T starting after second dose of radium-223&#xD;
Sipuleucel-T: 3 infusions of sipuleucel-T alone</description>
          </group>
          <group group_id="O2">
            <title>Sipuleucel-T Alone</title>
            <description>Sipuleucel-T will be administered intravenously per standard of care every 2 weeks at weeks 6, 8, and 10&#xD;
Sipuleucel-T: 3 infusions of sipuleucel-T alone</description>
          </group>
        </group_list>
        <measure>
          <title>Sipuleucel-T Product Immune Parameters as Assessed by Number of CD54+ Cells</title>
          <description>Mean number of CD54 + cells</description>
          <population>Data was only collected from 14 out of 16 participants in the Sipuleucel-T and radium 223 combination arm and 14 out of 16 participants in the Sipuleucel-T arm</population>
          <units>cells x 10 ^ 6</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2730.3" lower_limit="1704.8" upper_limit="3474.5"/>
                    <measurement group_id="O2" value="2059.1" lower_limit="1598.2" upper_limit="2512.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sipuleucel-T Product Immune Parameters as Assessed by CD54+ Upregulation</title>
        <description>Mean CD54+ Upregulation of Sipuleucel-T</description>
        <time_frame>Up to 4 weeks</time_frame>
        <population>Data was only collected from 14 out of 16 participants in the Sipuleucel-T and radium 223 combination arm and 14 out of 16 participants in the Sipuleucel-T arm</population>
        <group_list>
          <group group_id="O1">
            <title>Sipuleucel-T and Radium 223 Combination</title>
            <description>Radium-223 will be administered by intravenous injection over 1 minute at 50kbq (1.35 microcurie) per kg body weight per standard of care every 4 weeks at weeks 0, 4, 8, 12, 16, and 20&#xD;
Sipuleucel-T will be administered intravenously per standard of care every 2 weeks at weeks 6, 8, and 10&#xD;
Radium-223: 6 infusions of radium-223 with 3 infusions of sipuleucel-T starting after second dose of radium-223&#xD;
Sipuleucel-T: 3 infusions of sipuleucel-T alone</description>
          </group>
          <group group_id="O2">
            <title>Sipuleucel-T Alone</title>
            <description>Sipuleucel-T will be administered intravenously per standard of care every 2 weeks at weeks 6, 8, and 10&#xD;
Sipuleucel-T: 3 infusions of sipuleucel-T alone</description>
          </group>
        </group_list>
        <measure>
          <title>Sipuleucel-T Product Immune Parameters as Assessed by CD54+ Upregulation</title>
          <description>Mean CD54+ Upregulation of Sipuleucel-T</description>
          <population>Data was only collected from 14 out of 16 participants in the Sipuleucel-T and radium 223 combination arm and 14 out of 16 participants in the Sipuleucel-T arm</population>
          <units>cells x 10^6</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.8" lower_limit="26.4" upper_limit="35.1"/>
                    <measurement group_id="O2" value="31.3" lower_limit="25.1" upper_limit="35.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sipuleucel-T Product Immune Parameters as Assessed by Total Nucleated Cell Count</title>
        <description>Mean number of Total Nucleated Cells</description>
        <time_frame>Up to 4 weeks</time_frame>
        <population>Data was only collected from 14 out of 16 participants in the Sipuleucel-T and radium 223 combination arm and 14 out of 16 participants in the Sipuleucel-T arm</population>
        <group_list>
          <group group_id="O1">
            <title>Sipuleucel-T and Radium 223 Combination</title>
            <description>Radium-223 will be administered by intravenous injection over 1 minute at 50kbq (1.35 microcurie) per kg body weight per standard of care every 4 weeks at weeks 0, 4, 8, 12, 16, and 20&#xD;
Sipuleucel-T will be administered intravenously per standard of care every 2 weeks at weeks 6, 8, and 10&#xD;
Radium-223: 6 infusions of radium-223 with 3 infusions of sipuleucel-T starting after second dose of radium-223&#xD;
Sipuleucel-T: 3 infusions of sipuleucel-T alone</description>
          </group>
          <group group_id="O2">
            <title>Sipuleucel-T Alone</title>
            <description>Sipuleucel-T will be administered intravenously per standard of care every 2 weeks at weeks 6, 8, and 10&#xD;
Sipuleucel-T: 3 infusions of sipuleucel-T alone</description>
          </group>
        </group_list>
        <measure>
          <title>Sipuleucel-T Product Immune Parameters as Assessed by Total Nucleated Cell Count</title>
          <description>Mean number of Total Nucleated Cells</description>
          <population>Data was only collected from 14 out of 16 participants in the Sipuleucel-T and radium 223 combination arm and 14 out of 16 participants in the Sipuleucel-T arm</population>
          <units>cells 10^6</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11580.5" lower_limit="7445.2" upper_limit="13961.0"/>
                    <measurement group_id="O2" value="12740.5" lower_limit="9127.8" upper_limit="14740.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Sipuleucel-T and Radium 223 Combination</title>
          <description>Radium-223 will be administered by intravenous injection over 1 minute at 50kbq (1.35 microcurie) per kg body weight per standard of care every 4 weeks at weeks 0, 4, 8, 12, 16, and 20&#xD;
Sipuleucel-T will be administered intravenously per standard of care every 2 weeks at weeks 6, 8, and 10&#xD;
Radium-223: 6 infusions of radium-223 with 3 infusions of sipuleucel-T starting after second dose of radium-223&#xD;
Sipuleucel-T: 3 infusions of sipuleucel-T alone</description>
        </group>
        <group group_id="E2">
          <title>Sipuleucel-T Alone</title>
          <description>Sipuleucel-T will be administered intravenously per standard of care every 2 weeks at weeks 6, 8, and 10&#xD;
Sipuleucel-T: 3 infusions of sipuleucel-T alone</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary Retention</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="16"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="16"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="16"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="16"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Flu Like Symptoms</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="16"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Edema Limbs</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Catheter Related Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>White Blood Cell Decreased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Platelet Count Decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary Retention</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Emmanuel Antonarakis, MD</name_or_title>
      <organization>Johns Hopkins University</organization>
      <phone>410-502-8341</phone>
      <email>eantona1@jhmi.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

